Actively Recruiting
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-03-05
600
Participants Needed
1
Research Sites
991 weeks
Total Duration
On this page
Sponsors
A
Abramson Cancer Center at Penn Medicine
Lead Sponsor
N
National Comprehensive Cancer Network
Collaborating Sponsor
AI-Summary
What this Trial Is About
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
CONDITIONS
Official Title
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have a solid, enhancing kidney tumor 4 cm or smaller found incidentally within the last 6 months
- Age 18 years or older and able to read, understand, and sign informed consent
- Willing to follow the treatment plan and timing requirements
You will not qualify if you...
- Suspicion of cancer spread to the kidney if another cancer was diagnosed within 2 years before joining the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Actively Recruiting
Research Team
N
Nirmish Singla
CONTACT
T
Tina Driscoll
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here